Saxagliptin Hydrochloride Patent Expiration
Saxagliptin Hydrochloride is used for managing type II diabetes. It was first introduced by Astrazeneca Ab
Saxagliptin Hydrochloride Patents
Given below is the list of patents protecting Saxagliptin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Onglyza | US7951400 | Coated tablet formulation and method | Nov 30, 2028 | Astrazeneca Ab |
| Onglyza | USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul 31, 2023
(Expired) | Astrazeneca Ab |
| Onglyza | US6395767 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb 16, 2021
(Expired) | Astrazeneca Ab |
Saxagliptin Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Saxagliptin Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Saxagliptin Hydrochloride. The first generic version for Saxagliptin Hydrochloride was by Amneal Pharmaceuticals Llc and was approved on Jul 31, 2023. And the latest generic version is by Sun Pharmaceutical Industries Ltd and was approved on Jul 31, 2023.
Given below is the list of companies who have filed for Saxagliptin Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. AMNEAL
Amneal Pharmaceuticals Llc has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 2.5MG BASE | tablet | Discontinued | ORAL | N/A | Jul 31, 2023 |
| EQ 5MG BASE | tablet | Discontinued | ORAL | N/A | Jul 31, 2023 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
2. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 2.5MG BASE | tablet | Prescription | ORAL | AB | Jul 31, 2023 |
| EQ 5MG BASE | tablet | Prescription | ORAL | AB | Jul 31, 2023 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
| United States |
| |||||||||
3. GLENMARK PHARMS LTD
Glenmark Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 2.5MG BASE | tablet | Prescription | ORAL | AB | Jul 31, 2023 |
| EQ 5MG BASE | tablet | Prescription | ORAL | AB | Jul 31, 2023 |
4. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 2.5MG BASE | tablet | Prescription | ORAL | AB | Jul 31, 2023 |
| EQ 5MG BASE
(reference standard) | tablet | Prescription | ORAL | AB | Jul 31, 2023 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
5. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Saxagliptin Hydrochloride. All of these versions come by the name SAXAGLIPTIN. Given below are the details of the strengths of this generic introduced by Sun Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 2.5MG BASE | tablet | Prescription | ORAL | AB | Jul 31, 2023 |
| EQ 5MG BASE | tablet | Prescription | ORAL | AB | Jul 31, 2023 |
Manufacturing Plant Locations New
Sun Pharm's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Sun Pharm as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||||||||||||
| India |
| |||||||||||||||||||||||||||||